Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cost-effectiveness analyses are routinely based on data from group averages, restricting its generalizibility to those with below- or above-average risk. A pharmaco-economic model that used individualized risks for fractures was developed in order to take into account patient heterogeneity.Data were obtained from The Health Improvement Network research database of general practitioners, comprising a UK general population of women aged more than 50 years (N = 330,000). Mortality and hip, vertebral, and other osteoporotic fracture risks for each individual were estimated by age, body mass index (BMI), smoking, and other clinical risk factors. Estimates on costs, EuroQol (EQ-5D) utilities, and treatment efficacy were obtained from a UK national report (the National Institute for Clinical Excellence) and outcomes were simulated over a 10-year period.It was found that the cost per quality-adjusted life-year (QALY) gained was lower in elderly women and in women with fracture history. There was a large variability in the cost-effectiveness with baseline fracture risk and with clinical risk factors. Patients with low BMI (<20) had considerable better cost-effectiveness than patients with high BMI (>or=26). Using a cost-acceptability ratio of 30k pounds per QALY gained, bisphosphonate treatment became cost-effective for patients with a 5-year risk of 9.3% (95% confidence interval [CI] 8.0-10.5%) for osteoporotic fractures and of 2.1% (95% CI 1.5-2.7%) for hip fractures. Including bone mineral density in the risk assessment, the cost per QALY gained was 35k pounds in women at age 60 with a fracture history and a T-score of -2.5 (at age 80, this was 3k pounds).A pharmacoeconomic model based on individual long-term risks of fracture improves the selection of postmenopausal women for cost-effective treatment with bisphosphonates.

Original publication

DOI

10.1111/j.1524-4733.2007.00188.x

Type

Journal article

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Publication Date

09/2007

Volume

10

Pages

348 - 357

Addresses

Utrecht University, Utrecht, The Netherlands. t.p.vanstaa@uu.nl

Keywords

Humans, Osteoporosis, Postmenopausal, Diphosphonates, Cohort Studies, Postmenopause, Bone Density, Quality-Adjusted Life Years, Aged, Aged, 80 and over, Middle Aged, Cost-Benefit Analysis, Economics, Pharmaceutical, Female, Bone Density Conservation Agents, Fractures, Bone, United Kingdom